Alignment Healthcare (NASDAQ:ALHC) Insider Sells $211,388.44 in Stock

Alignment Healthcare, Inc. (NASDAQ:ALHC) insider Andreas Wagner sold 11,602 shares of the firm’s stock in a transaction that occurred on Thursday, March 19th. The stock was sold at an average price of $18.22, for a total transaction of $211,388.44. Following the sale, the insider owned 148,628 shares of the company’s stock, valued at $2,708,002.16. The trade was a 7.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Alignment Healthcare Price Performance

NASDAQ ALHC opened at $17.34 on Friday. The stock has a market capitalization of $3.54 billion, a P/E ratio of -1,732.27, a P/E/G ratio of 2.54 and a beta of 1.18. Alignment Healthcare, Inc. has a 1 year low of $11.63 and a 1 year high of $23.87. The business’s fifty day moving average is $20.44 and its two-hundred day moving average is $18.80. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.71 and a current ratio of 1.71.

Alignment Healthcare (NASDAQ:ALHC) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.10. The company had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. Alignment Healthcare had a negative return on equity of 0.49% and a negative net margin of 0.02%.The company’s quarterly revenue was up 44.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.16) EPS. On average, research analysts forecast that Alignment Healthcare, Inc. will post -0.69 earnings per share for the current fiscal year.

Key Alignment Healthcare News

Here are the key news stories impacting Alignment Healthcare this week:

• Positive Sentiment: Strong fundamentals — Alignment reported Q4 revenue of ~$1.01B and an EPS beat (‑$0.05 vs. consensus ‑$0.15) with revenue up ~44% YoY, which supports longer‑term growth expectations. Earnings Summary
• Positive Sentiment: Analyst bullishness — Multiple brokerages have raised price targets and maintain Buy/Overweight views (e.g., TD Cowen, JPMorgan, KeyCorp, Robert W. Baird), leaving a consensus analyst stance that is constructive for the stock. Analyst Coverage
• Neutral Sentiment: Short‑interest data published for March appears erroneous (shows 0 shares / NaN changes). Do not treat those figures as evidence of new short pressure until exchanges correct the data.
• Neutral Sentiment: High institutional ownership (~86%) can mute volatility from retail flows but also means institutional positioning matters for future moves; a Zacks comparison piece contrasts ALHC with peers for valuation context. BTSG or ALHC: Which Is the Better Value Stock Right Now?
• Negative Sentiment: Secondary offering announced by a major shareholder — the planned secondary raises potential near‑term selling supply and is a clear negative for price action until the offering size and timing are known. Alignment Healthcare announces secondary offering by major shareholder
• Negative Sentiment: Clustered insider selling — several senior executives reported sales on Mar 18–19 (CEO John E. Kao: 73,046 shares; President Dawn Maroney: 36,749; COO Sebastian Burzacchi: 15,361; plus multiple other officers, and Robert Scavo sold 11,285). These simultaneous disposals (~tens of thousands of shares each at ~$17.84) create headline risk and likely contributed to today’s negative sentiment. Representative SEC filings: Kao — Kao SEC Filing, Scavo — Scavo SEC Filing

Institutional Trading of Alignment Healthcare

Hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. grew its holdings in shares of Alignment Healthcare by 10.9% during the fourth quarter. Vanguard Group Inc. now owns 15,492,802 shares of the company’s stock valued at $305,983,000 after buying an additional 1,524,218 shares in the last quarter. Wellington Management Group LLP lifted its stake in Alignment Healthcare by 26.9% in the 4th quarter. Wellington Management Group LLP now owns 14,070,893 shares of the company’s stock worth $277,900,000 after acquiring an additional 2,981,166 shares in the last quarter. T. Rowe Price Investment Management Inc. lifted its stake in Alignment Healthcare by 0.6% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 12,643,784 shares of the company’s stock worth $249,715,000 after acquiring an additional 79,268 shares in the last quarter. Invesco Ltd. boosted its position in Alignment Healthcare by 38.9% during the 4th quarter. Invesco Ltd. now owns 6,202,592 shares of the company’s stock worth $122,501,000 after acquiring an additional 1,735,962 shares during the period. Finally, Hood River Capital Management LLC boosted its position in Alignment Healthcare by 6.0% during the 2nd quarter. Hood River Capital Management LLC now owns 5,517,336 shares of the company’s stock worth $77,243,000 after acquiring an additional 311,424 shares during the period. Institutional investors and hedge funds own 86.19% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alignment Healthcare in a research report on Wednesday, January 21st. KeyCorp reaffirmed an “overweight” rating and set a $28.00 price objective on shares of Alignment Healthcare in a research note on Thursday, January 22nd. TD Cowen raised their target price on shares of Alignment Healthcare from $18.50 to $25.00 and gave the stock a “buy” rating in a report on Friday, January 16th. JPMorgan Chase & Co. lifted their target price on shares of Alignment Healthcare from $23.00 to $26.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. Finally, Wall Street Zen lowered shares of Alignment Healthcare from a “buy” rating to a “hold” rating in a report on Saturday, March 7th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $24.56.

About Alignment Healthcare

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.